Transtorine — predicted protein targets

Known targets — ChEMBL curated mechanism

ABCC9 ABL1 ACE ACHE ACVR1 ADORA1 ADORA2A ADORA2B ADORA3 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 AGTR1 ALOX5 ATP4A ATP4B BCR BTK CACNA1A CACNA1B CACNA1C CACNA1D CACNA1E CACNA1F CACNA1G CACNA1H CACNA1I CACNA1S CACNA2D1 CACNA2D2 CACNA2D3 CACNA2D4 CACNB1 CACNB2 CACNB3 CACNB4 CACNG1 CACNG2 CACNG3 CACNG4 CACNG5 CACNG6 CACNG7 CACNG8 CALCRL CFB CHRM1 CHRM2 CHRM3 CHRM4 CHRM5 CHRNA1 CHRNB1 CHRND CHRNE CHRNG CRBN CUL4A CXCR1 CXCR2 DDB1 DDC DHFR DPP4 DRD2 DRD3 DRD4 EGFR ERBB2 ERBB4 ESR1 ESR2 FDPS FKBP1A FLT1 FLT3 FLT4 GART GHSR GRIA1 GRIA2 GRIA3 GRIA4 GRIK1 GRIK2 GRIK3 GRIK4 GRIK5 GRIN2A GSK3A GSK3B HDAC1 HDAC10 HDAC11 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HRH1 HTR1A HTR1B HTR1D HTR1E HTR1F HTR2A HTR2B HTR2C HTR3A HTR3B HTR3C HTR3D HTR3E HTR4 HTR5A HTR6 HTR7 IDH1 IDH2 IMPA1 ITGA2B ITGB3 JAK1 JAK2 JAK3 KCNJ11 KCNK3 KCNK9 KDR KIT MEN1 MET MMP1 MMP13 MMP7 MMP8 NA NOD2 NS5b ODC1 OPG057 OPRD1 OPRK1 OPRM1 P PARP1 PARP2 PDE3A PDE3B PDE4A PDE4B PDE4C PDE4D PDGFRB PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 PIK3R5 PKLR PPARD PPAT PTGS1 PTGS2 RBX1 ROCK1 ROCK2 RRM1 RRM2 RRM2B SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SCNN1A SCNN1B SCNN1G SIGMAR1 SLC10A2 SLC5A2 SLC6A2 SLC6A3 SLC6A4 SLC9A3 SYK TACR1 THRA THRB TOP1 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 TYK2 TYMS VDR ampC bla blaT-3 blaT-4 blaT-5 blaT-6 blaUOE-1 dacA dacB dacC folA folP ftsI gyrA gyrB ileS mecA mrcA mrcB mrdA parC parE pbp2 pbp4 pbpA pbpF rplA rplB rplC rplD rplE rplF rplI rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmE2 rpmF rpmG rpmG1 rpmG2 rpmG3 rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU thyA ykgM ykgO

The experimentally established mechanism targets of Transtorine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	THRB known ✓	P10828	1/20	0.46

▸	ALOX15	P16050	3/20	0.58

▸	MGAM	O43451	1/20	0.52

▸	ALDH1A1	P00352	3/20	0.50

▸	HPGD	P15428	1/20	0.50

▸	HSD17B10	Q99714	1/20	0.50

▸	PDE10A	Q9Y233	3/20	0.45

▸	SMN1; SMN2	Q16637	2/20	0.45

▸	KDM4E	B2RXH2	2/20	0.45

▸	LMNA	P02545	1/20	0.45

▸	IGFBP3	P17936	2/20	0.44

▸	MYC	P01106	1/20	0.44

▸	MAX	P61244	1/20	0.44

▸	POLB	P06746	1/20	0.44

▸	MAPT	P10636	1/20	0.44

▸	DHODH	Q02127	2/20	0.44

▸	IGFBP5	P24593	1/20	0.43

▸	TSHR	P16473	1/20	0.42

▸	ACMSD	Q8TDX5	1/20	0.42

▸	TDP1	Q9NUW8	1/20	0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Transtorine SCHEMBL480985	1.00	ALOX15 (0.58)	ALOX15MGAMALDH1A1HPGDHSD17B10
Transtorine SCHEMBL17596601	0.98	ALOX15 (0.60)	ALOX15MGAMALDH1A1HPGDHSD17B10
Transtorine SCHEMBL22979	0.98	ALOX15 (0.60)	ALOX15MGAMALDH1A1HPGDHSD17B10
Transtorine SCHEMBL21384236	0.85	ALOX15 (0.48)	ALOX15MGAMALDH1A1HPGDHSD17B10
SCHEMBL247555	0.84	GRM2 (0.59)	ALDH1A1
SCHEMBL17718271	0.84	ALDH1A1 (0.49)	ALOX15MGAMALDH1A1HPGDHSD17B10
Transtorine SCHEMBL10895515	0.82	G6PD (0.59)	ALOX15ALDH1A1HPGDTHRBPDE10A
Transtorine SCHEMBL7937597	0.82	ALDH1A1 (0.44)	ALOX15MGAMALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL17769122	0.82	GRM2 (0.57)	ALDH1A1
SCHEMBL11827386	0.80	IGFBP5 (0.47)	ALOX15MGAMALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2017037616-A1	ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS	LUPIN LIMITED (IN)	2017-03-09	—	—	WO	disclosed
EP-2778156-B1	Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states	ASTRAZENECA AB (SE)	2016-11-30	—	—	EP	disclosed
EP-2778156-A1	Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states	AstraZeneca AB (Publ) (SE)	2014-09-17	—	—	EP	disclosed
CN-102105448-B	Phenoxypyridinylamide derivatives and use thereof in the treatment of PDE4 mediated disease states	ASTRAZENECA AB	2013-11-13	—	—	CN	disclosed
US-8273774-B2	Phenoxypyridinylamide compounds	ASTRAZENECA AB (SE)	2012-09-25	—	—	US	disclosed
CN-1867550-B	Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders	DPHARM LTD	2012-08-15	—	—	CN	disclosed
CN-102105448-A	Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states	ASTRAZENECA AB	2011-06-22	—	—	CN	disclosed
EP-2297106-A1	PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES	AstraZeneca AB (SE)	2011-03-23	—	—	EP	disclosed
US-7745426-B2	Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders	D-PHARM LTD. (IL)	2010-06-29	—	—	US	disclosed
US-20100041638-A1	Chemical Compounds 293	ASTRAZENECA AB (SE)	2010-02-18	—	—	US	disclosed
WO-2009144494-A1	PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES	ASTRAZENECA AB (SE)	2009-12-03	—	—	WO	disclosed
EP-1654231-A4	COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS	DPHARM LTD (IL)	2009-03-11	—	—	EP	disclosed
CN-1867550-A	Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders	DPHARM LTD (IL)	2006-11-22	—	—	CN	disclosed
US-20060235000-A1	Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders	D-PHARM LTD. (IL)	2006-10-19	—	—	US	disclosed
EP-1654231-A2	COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS	D-Pharm Ltd. (IL)	2006-05-10	—	—	EP	disclosed
WO-2005016228-A2	COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS	D-PHARM LTD. (IL)	2005-02-24	—	—	WO	disclosed
EP-1126833-A4	OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF	TREGA BIOSCIENCES INC (US)	2004-09-08	—	—	EP	disclosed
EP-1126833-A2	OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF	TREGA BIOSCIENCES, INC. (US)	2001-08-29	—	—	EP	disclosed
WO-2000025768-A1	OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF	TREGA BIOSCIENCES, INC. (US)	2000-05-11	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100041638-A1	Chemical Compounds 293	PDE4B, PDE4A, PDE3B	THRB 2930/4885ALOX15 2847/4885MGAM 2209/4885
US-20060235000-A1	Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders	PNPO, CYP2B6, CHRNA6	THRB 2078/4885ALOX15 496/4885MGAM 2495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.